leadf
logo-loader
viewHelix BioPharma Corp.

Helix BioPharma announces data from L-DOS47 dose escalation study of non-small cell lung cancer patients

The company said L-DOS4, in combination with pemetrexed and carboplatin, appeared to be well tolerated with promising anti-tumor activity

Helix BioPharma Corp. - Helix BioPharma Corp announces topline data from a recent L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in non-squamounon-small cell lung cancer
The Phase 1 dose escalation study involved 14 patients and data will be published at the ASCO 2020 annual conference

Helix BioPharma Corp (TSX:HBP) (OCTMKTS:HBPCF) announced Thursday that topline data from a recent L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in non-squamous non-small cell lung cancer will be published at the ASCO 2020 annual conference.

“We are very optimistic with L-DOS47’s demonstrated excellent safety profile and encouraging efficacy data,” said CEO Dr Heman Chao in a statement.

Helix said the Phase 1 dose escalation study involved 14 patients with recurrent or metastatic non-squamous non-small cell lung cancer enrolled across six dosing cohorts, and that no dose limiting toxicities were observed.

READ: Helix BioPharma maintaining business continuity amid coronavirus pandemic

Of the 12 patients evaluated for efficacy, five patients (41.7%) had a partial response, four patients (33.3%) experienced stable disease and three patients (25%) had progressive disease.

Helix said the objective response rate was 41.7% and the clinical benefit rate 75.0%, noting that L-DOS47 appeared to be well tolerated with promising anti-tumor activity. 

“I would like to thank the patients and their families who participated in our clinical study, as well as the principal investigators and associates who helped conduct the study,” said Dr Chao.

The ASCO conference will be held virtually from May 29-31 

Shares in Toronto nudged up 3.31% to C$1.25.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Helix BioPharma Corp.

Price: 0.89 CAD

TSX:HBP
Market: TSX
Market Cap: $125.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Helix BioPharma Corp. named herein, including the promotion by the Company of Helix BioPharma Corp. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Helix BioPharma extends Moffitt cancer center collaboration to further...

Helix BioPharma Corp (TSX:HBP) (OTCMKTS:HBPCF) CEO Heman Chao tells Proactive the immuno-oncology focused biotech has extended its collaboration with the Florida-based Moffitt Cancer Center for a further year, building on the pair's progress so far. Chao says Helix and Moffitt have already...

on 08/13/2020

2 min read